Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 8/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645986 | 0.92 | ABCB1 (0.66) | MAPTNPSR1HTTKMT2ANPC1 | |
| SCHEMBL11222561 | 0.90 | MAPT (0.57) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL11277169 | 0.89 | MAPT (0.56) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL7828438 | 0.87 | MAPT (0.54) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL11277648 | 0.86 | MAPT (0.53) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL11287679 | 0.85 | ABCB1 (0.66) | MAPTNPSR1HTTKMT2ANPC1 | |
| SCHEMBL12426042 | 0.85 | HTT (0.82) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL29657482 | 0.85 | MAPT (0.66) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL1532370 | 0.85 | MAPT (0.66) | MAPTNPSR1HTTKMT2APOLB | |
| SCHEMBL4835079 | 0.85 | MAPT (0.66) | MAPTNPSR1HTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730102-B1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3 , 4,4'-TETRAMINOBIPHENYL | COUNCIL SCIENT IND RES (IN) | 2010-09-22 | — | — | EP | claimed |
| EP-1730102-A1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3 , 4,4'-TETRAMINOBIPHENYL | Council of Scientific and Industrial Research (IN) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092839-A1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3', 4,4'-TETRAMINOBIPHENYL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-10-06 | — | — | WO | claimed |
| CN-108191674-A | A kind of synthetic method of benzidine compound | 邵玉田 | 2018-06-22 | — | — | CN | disclosed |
| US-7999112-B2 | Reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3′-diaminobenzidine and its analogues and a process thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-08-16 | — | — | US | disclosed |
| EP-1730102-B1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3 , 4,4'-TETRAMINOBIPHENYL | COUNCIL SCIENT IND RES (IN) | 2010-09-22 | — | — | EP | disclosed |
| US-7601873-B2 | Method of manufacturing 3,3′,4,4′-tetraaminobiphenyl | SHOWA DENKO K.K. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601873-B2 | Method of manufacturing 3,3′,4,4′-tetraaminobiphenyl | SHOWA DENKO K.K. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090149676-A1 | METHOD OF MANUFACTURING 3, 3' , 4, 4'-TETRAAMINOBIPHENYL | SHOWA DENKO K. K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149676-A1 | METHOD OF MANUFACTURING 3, 3' , 4, 4'-TETRAAMINOBIPHENYL | SHOWA DENKO K. K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090131678-A1 | Novel reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3'-diaminobenzidine and its analogues and a process thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2009-05-21 | — | — | US | disclosed |
| EP-1730102-A1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3 , 4,4'-TETRAMINOBIPHENYL | Council of Scientific and Industrial Research (IN) | 2006-12-13 | — | — | EP | disclosed |
| US-6979749-B2 | Catalytic process for the production of 3,3′, 4,4′-tetraminobiphenyl | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-12-27 | — | — | US | disclosed |
| WO-2005092839-A1 | A NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3', 4,4'-TETRAMINOBIPHENYL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215823-A1 | NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3', 4,4'-TETRAMINOBIPHENYL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-09-29 | — | — | US | disclosed |
| US-6835854-B1 | Oxidation of 3,3'-dichloro 4,4'-diaminobiphenyl (DCB), ammonolysis of the resulting 3,3'-dichloro-4,4'-dinitrobiphenyl (DCDNB) and reduction of 3,3'-diamino-4,4'-dinitrobiphenyl and treating with an alkali | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149676-A1 | METHOD OF MANUFACTURING 3, 3' , 4, 4'-TETRAAMINOBIPHENYL | BRI3BP, TH, TST | MAPT 2656/4885NPSR1 2357/4885HTT 147/4885 |
| US-20050215823-A1 | NOVEL CATALYTIC PROCESS FOR THE PRODUCTION OF 3,3', 4,4'-TETRAMINOBIPHENYL | NNMT, CBR3, POR | MAPT 4350/4885NPSR1 1305/4885HTT 2171/4885 |
| US-20090131678-A1 | Novel reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3'-diaminobenzidine and its analogues and a process thereof | CYBB, DDT, NOX4 | MAPT 3729/4885NPSR1 3055/4885HTT 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.